Trial Profile
A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza HA vaccine (Flubio)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo
- 04 Nov 2015 New source identified and integrated; Japan Pharmaceutical Information Center - Clinical Trials Information record (JapicCTI142493)
- 04 Nov 2015 New trial record
- 28 Oct 2015 Primary endpoint has been met. (The difference between the seroconversion rates and the ratio of GMTs of HI antibody titer against three vaccine stains at Day 21), as per an article published in the Vaccine.